NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis → Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press) (Ad) Free LXEO Stock Alerts $14.64 0.00 (0.00%) (As of 10:38 AM ET) Add Compare Share Share Today's Range$14.56▼$14.7950-Day Range$12.05▼$18.7652-Week Range$9.00▼$22.33Volume6,167 shsAverage Volume126,312 shsMarket Capitalization$482.24 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lexeo Therapeutics alerts: Email Address Lexeo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside50.3% Upside$22.00 Price TargetShort InterestHealthy3.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.55 out of 5 starsMedical Sector402nd out of 895 stocksBiological Products, Except Diagnostic Industry52nd out of 150 stocks 3.6 Analyst's Opinion Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.10% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexeo Therapeutics has recently decreased by 20.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXEO. Previous Next 2.5 News and Social Media Coverage News SentimentLexeo Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lexeo Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for LXEO on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lexeo Therapeutics are expected to remain at ($2.65) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?Click here to see it because he believes this new venture… About Lexeo Therapeutics Stock (NASDAQ:LXEO)Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Read More LXEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXEO Stock News HeadlinesJune 22, 2024 | americanbankingnews.comHead-To-Head Survey: Biogen (NASDAQ:BIIB) and Lexeo Therapeutics (NASDAQ:LXEO)May 9, 2024 | globenewswire.comLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsJune 27, 2024 | Paradigm Press (Ad)Elon’s Next IPO Could be Bigger than TeslaYou now have a second chance with what I believe could be Elon’s next big IPO.May 7, 2024 | globenewswire.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy AdvancementsApril 24, 2024 | uk.investing.comLexeo Therapeutics secures rights to advance gene therapyApril 22, 2024 | finance.yahoo.comLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyApril 16, 2024 | marketwatch.comLexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia CardiomyopathyJune 27, 2024 | Paradigm Press (Ad)Elon’s Next IPO Could be Bigger than TeslaYou now have a second chance with what I believe could be Elon’s next big IPO.April 16, 2024 | markets.businessinsider.comLexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-marketApril 16, 2024 | finance.yahoo.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyApril 16, 2024 | globenewswire.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia CardiomyopathyApril 9, 2024 | seekingalpha.comLexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay OffMarch 14, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)March 13, 2024 | globenewswire.comLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingMarch 13, 2024 | markets.businessinsider.comOptimistic Outlook for Lexeo Therapeutics with Strong Clinical and Financial Performance Justifying Buy RatingMarch 12, 2024 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To KnowMarch 11, 2024 | msn.comLexeo Therapeutics announces $95M private equity placementMarch 11, 2024 | globenewswire.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 11, 2024 | globenewswire.comLexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingFebruary 6, 2024 | msn.comLexeo Therapeutics Bolsters Leadership with Key HiresFebruary 5, 2024 | msn.comLexeo Therapeutics announces new executive appointmentsFebruary 5, 2024 | finance.yahoo.comLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsJanuary 29, 2024 | seekingalpha.comLexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer'sJanuary 19, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO) and Andlauer Healthcare Group (OtherANDHF)January 7, 2024 | seekingalpha.comLXEO Lexeo Therapeutics, Inc.January 6, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC CapitalSee More Headlines Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/27/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CUSIPN/A CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$28.00 Low Stock Price Target$19.00 Potential Upside/Downside+50.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($22.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-155.79% Return on Assets-51.08% Debt Debt-to-Equity Ratio0.01 Current Ratio9.16 Quick Ratio9.16 Sales & Book Value Annual Sales$650,000.00 Price / Sales741.91 Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book3.44Miscellaneous Outstanding Shares32,940,000Free Float31,462,000Market Cap$482.24 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. R. Nolan Townsend (Age 43)CEO & Director Comp: $864.34kDr. Eric Adler M.D. (Age 50)Chief Medical Officer & Head of Research Comp: $623.4kMs. Jenny R. Robertson (Age 49)Chief Business & Legal Officer Comp: $617.9kDr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardDr. Paul B. McCormac Ph.D. (Age 54)Chief Technical Officer Comp: $471.73kDr. Jordan Shin M.D.Ph.D., Senior Vice President of Clinical Development & Translational Science, CardiologyDr. Jordan S. Dubow M.D. (Age 45)Head of CNS Clinical Development Dr. Sandi See Tai M.D. (Age 53)Chief Development Officer Mr. Ryan McHenryVP & Corporate ControllerMore ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXKymera TherapeuticsNASDAQ:KYMRBeam TherapeuticsNASDAQ:BEAMFusion PharmaceuticalsNASDAQ:FUSNImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 198,281 shares on 5/17/2024Ownership: 2.434%RA Capital Management L.P.Bought 660,938 shares on 5/17/2024Ownership: 2.006%Janus Henderson Group PLCBought 210,047 shares on 5/16/2024Ownership: 7.713%American International Group Inc.Bought 5,053 shares on 5/14/2024Ownership: 0.015%Vanguard Group Inc.Bought 65,573 shares on 5/10/2024Ownership: 1.462%View All Insider TransactionsView All Institutional Transactions LXEO Stock Analysis - Frequently Asked Questions Should I buy or sell Lexeo Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexeo Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LXEO shares. View LXEO analyst ratings or view top-rated stocks. What is Lexeo Therapeutics' stock price target for 2024? 9 analysts have issued 12 month price objectives for Lexeo Therapeutics' shares. Their LXEO share price targets range from $19.00 to $28.00. On average, they anticipate the company's share price to reach $22.00 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View analysts price targets for LXEO or view top-rated stocks among Wall Street analysts. How have LXEO shares performed in 2024? Lexeo Therapeutics' stock was trading at $13.42 at the beginning of the year. Since then, LXEO stock has increased by 9.1% and is now trading at $14.64. View the best growth stocks for 2024 here. When is Lexeo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 4th 2024. View our LXEO earnings forecast. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.01. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $100 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share. When did Lexeo Therapeutics' lock-up period expire? Lexeo Therapeutics' lock-up period expired on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its IPO on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. Since the end of Lexeo Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Lexeo Therapeutics' major shareholders? Lexeo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (7.71%), Artal Group S.A. (2.43%), RA Capital Management L.P. (2.01%), Vanguard Group Inc. (1.46%), Cornell University (0.38%) and American International Group Inc. (0.02%). View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXEO) was last updated on 6/27/2024 by MarketBeat.com Staff From Our PartnersDon't miss the boom: This psychedelic stock may be ready to rocket.Discover how an exciting pipeline and a possible FDA approval may help this biotech company see incredible gro...ATAI | Sponsored[URGENT] This one stock is redefining retirementWhat I tell you now might sound unbelievable, but I need you to read to the end. Because I am going to tell...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWho is Investor X and why are they betting big on nickel?Nickel is fast becoming one of the most important - and most valuable - commodities today. It's essential f...The Tomorrow Investor | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.